Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 2Neoplasms 1Nasopharyngeal Carcinoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Liver Cirrhosis 1Leukemia, Myeloid, Acute 1Intellectual Disability 1Heart Failure 1Gynecologic Cancer 1Carcinoma, Non-Small-Cell Lung 1Blood Loss, Surgical 1Arrhythmias, Cardiac 1

Interventions

Ivabradine 2Watchful Waiting 1Standard of Care 1Spironolactone 1Secondary Prevention 1Population Groups 1Perindopril 1Hydroxymethylglutaryl-CoA Reductase Inhibitors 1Exercise 1Control Groups 1Blood Specimen Collection 1Bisoprolol 1Atorvastatin 1Antineoplastic Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Heart Failure × Population Groups × Clear all
NCT06092606 2023-10-23

A Multicenter Clinical Trial on DH001 Tablets in the Prevention of Doxorubicin-induced Cardiotoxicity in Cancer Patients

Monyan Pharmaceutical (Shanghai) Co., Ltd.

Phase 2 Unknown
90 enrolled

Arrhythmias, Cardiac, Heart Failure, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡